WHO Approves Two New RSV Vaccines to Protect Infants Worldwide

The World Health Organization (WHO) has officially recommended two groundbreaking immunization tools aimed at protecting infants from Respiratory Syncytial Virus (RSV)—a leading cause of acute lower respiratory infections in young children. These new vaccines are expected to significantly reduce hospitalizations and deaths, particularly in low- and middle-income countries, where 97% of RSV-related deaths occur.

A New Era of RSV Prevention

WHO's recommendations include:

·       A maternal vaccine administered to pregnant women in their third trimester, offering newborns immediate protection.

·       A long-acting antibody injection for infants, which begins working within a week of administration and provides at least five months of immunity.

RSV infection is especially harmful to infants, particularly those born prematurely. WHO immunization expert Dr. Kate O’Brien emphasized that half of all RSV-related deaths occur in babies younger than six months. The new vaccines could transform RSV prevention, dramatically reducing severe cases and saving thousands of infant lives worldwide.

Global Reactions & Implementation Push

The approval of these vaccines has been met with enthusiasm from health experts, parents, and public health advocates. Many applaud WHO’s move, recognizing that early immunization could drastically cut the global burden of RSV-related illnesses.

WHO is urging all countries to integrate either the maternal vaccine or antibody injection into their national immunization programs to maximize coverage and impact. Experts stress that swift implementation is critical in regions with high RSV mortality rates.

With these new tools, the fight against RSV takes a major leap forward—bringing hope for safer, healthier beginnings for new-borns across the world.